Regulation, role, and targeting of Akt in cancer

Journal of Clinical Oncology

Volumn 29, Issue 35, 2011, Pages 4715-4717

  Davies, Michael A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; G PROTEIN COUPLED RECEPTOR; GLUCOSE; GROWTH FACTOR; ISOPROTEIN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MK 2206; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLECKSTRIN; PROTEIN KINASE B; PROTEIN KINASE B ALPHA; PROTEIN KINASE B BETA; PROTEIN KINASE B GAMMA; PROTEIN KINASE B INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL METABOLISM; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME SUBSTRATE; EPITHELIAL MESENCHYMAL TRANSITION; GENE DELETION; GENE MUTATION; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HAIR FOLLICLE; HYPERGLYCEMIA; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; NEOPLASM; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; SCIENTIFIC LITERATURE; SEQUENCE HOMOLOGY; TUMOR BIOPSY;

FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 83255188843     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.4751     Document Type: Article

References (37)

1. Staal SP, Hartley JW, Rowe WP: Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci U S A 74:3065-3067, 1977 (Pubitemid 8132494)
2. Yap TA, Yan L, Patnaik A, et al.: First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29:4688-4695, 2011
3. Bellacosa A, Testa JR, Moore R, et al.: A portrait of AKT kinases: Human cancer and animal models depict a family with strong individualities. Cancer Biol Ther 3:268-275, 2004 (Pubitemid 41350878)
4. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296:1655-1657, 2002
5. Sarbassov DD, Guertin DA, Ali SM, et al.: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101, 2005 (Pubitemid 40262113)
6. Bozulic L, Surucu B, Hynx D, et al.: PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 30:203-213, 2008 (Pubitemid 351626686)
7. Courtney KD, Corcoran RB, Engelman JA: The PI3K pathway as drug target in Human Cancer. J Clin Oncol 28:1075-1083, 2010
8. Fayard E, Xue G, Parcellier A, et al.: Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Curr Top Microbiol Immunol 346: 31-56, 2010
9. Vasudevan KM, Garraway LA: AKT signaling in physiology and disease. Curr Top Microbiol Immunol 347:105-133, 2010
10. Cho H, Mu J, Kim JK, et al.: Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292:1728-1731, 2001 (Pubitemid 32506248)
11. Easton RM, Cho H, Roovers K, et al.: Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 25:1869-1878, 2005 (Pubitemid 40280150)
12. Cheung M, Sharma A, Madhunapantula SV, et al.: Akt3 and mutant V600EB-Raf cooperate to promote early melanoma development. Cancer Res 68:3429-3439, 2008
13. Stahl JM, Sharma A, Cheung M, et al.: Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64:7002-7010, 2004 (Pubitemid 39331010)
14. Irie HY, Pearline RV, Grueneberg D, et al.: Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 171:1023-1034, 2005 (Pubitemid 41815834)
15. Mass RD, Press MF, Anderson S, et al.: Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6:240-246, 2005 (Pubitemid 47050800)
16. Piccart-Gebhart MJ, Procter M, Leyland- Jones B, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
17. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005 (Pubitemid 41464706)
18. Chapman PB, Hauschild A, Robert C, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
19. Davies M, Hennessy B, Mills GB: Point mutations of protein kinases and individualised cancer therapy. Expert Opin Pharmacother 7:2243-2261, 2006
20. Yuan TL, Cantley LC: PI3K pathway alterations in cancer: Variations on a theme. Oncogene 27:5497-5510, 2008
21. Li J, Yen C, Liaw D, et al.: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947, 1997 (Pubitemid 27148818)
22. Wu H, Goel V, Haluska FG: PTEN signaling pathways in melanoma. Oncogene 22:3113-3122, 2003 (Pubitemid 36713763)
23. Zhou XP, Gimm O, Hampel H, et al.: Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157:1123-1128, 2000
24. Steck PA, Pershouse MA, Jasser SA, et al.: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362, 1997 (Pubitemid 27147102)
25. Davies MA, Stemke-Hale K, Lin E, et al.: Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 15:7538-7546, 2009
26. Park ES, Rabinovsky R, Carey M, et al.: Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 9:257-267, 2010
27. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al.: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer Cancer Res 68:6084-6091, 2008
28. Vasudevan KM, Barbie DA, Davies MA, et al.: AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16:21-32, 2009
29. Dankort D, Curley DP, Cartlidge RA, et al.: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-552, 2009
30. Tsao H, Goel V, Wu H, et al.: Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Investig Dermatol 122:337-341, 2004 (Pubitemid 38281053)
31. Chandarlapaty S, Sawai A, Scaltriti M, et al.: AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19:58-71, 2011
32. Mirzoeva OK, Das D, Heiser LM, et al.: Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells toMEKinhibition. Cancer Res 69:565-572, 2009
33. Gopal YN, Deng W, Woodman SE, et al.: Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70:8736-8747, 2010
34. Villanueva J, Vultur A, Lee JT, et al.: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695, 2010
35. O'Reilly KE, Rojo F, She QB, et al.: MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508, 2006 (Pubitemid 43259931)
36. Tabernero J, Rojo F, Calvo E, et al.: Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603-1610, 2008
37. Lu Y, Muller M, Smith D, et al.: Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene [epub ahead of print on June 13, 2011] DOI: 10.1200/JCO.2011.37.4751; published online ahead of print at www.jco.org on October 24, 2011